CBX7 embraces multifaceted roles across distinct tumor types, involving its downregulation in renal clear cell carcinoma and its association with favorable prognoses, suppression of BLBC growth and metastasis via the Twist1/EphA2 pathway, and a paradoxical involvement in bladder cancer, wherein it dampens FGFR3 expression to attenuate cisplatin sensitivity [39, 40]. The gene discussed is EPHA2; the disease is urinary bladder cancer.